（来源：市场星报） 为深入落实长三角一体化发展国家战略，推动医疗器械审评标准区域统一，长三角三省一市医疗器械审 评部门于日前联合发布长三角区域第二类医疗器械注册12项技术审评要点，旨在以区域协作配合，为长 三角医疗器械质量安全、产业创新发展提供强有力的技术支撑。 此次联合发布的审评要点，是在《长三角区域医疗器械技术审评合作协议》框架下，结合区域医疗器械 产业特色、审评查验实践经验，经多轮专家论证、企业调研及跨区域研讨形成的共识，涵盖动态心电记 录仪、基因测序文库制备仪等重点产品，兼顾合规监管与产业创新双重需求。 该批审评要点的发布，不仅统一了区域审评标准与技术要求，解决了企业跨区域申报中"标准差异、重 复准备"的痛点、难点，也降低了企业申报成本，提升了申报效率。同时，发布的云计算平台、可穿戴 设备等前沿类别产品，也与我省医疗器械产业创新发展趋势紧密贴合，为我省高端医疗器械产业集群培 育、创新成果转化提供了坚实技术支持。 省药品审评查验中心相关负责人表示，该中心将持续坚守审评检查职责使命，深化与长三角区域审评检 查机构的协同联动，积极参与区域审评标准优化完善、能力共建共享等工作。同时，立足我省医疗器械 产业发展 ...

本报记者 刘钊 对不少肿瘤患者而言，最难的并非某一次治疗本身，而是出院后的"漫长空窗期"：复查节点如何安排、 化疗副作用如何监测、检验报告怎么看、夜间突发不适找谁咨询……现实中，医疗服务的"时空限 制"与"服务断层"，常常让患者在院外陷入"失管"困局。 在此背景下，盈康生命科技股份有限公司（以下简称"盈康生命"）发布肿瘤全周期管理智能体，并提出 以此为核心载体推进战略升级，在医疗服务板块实现从诊疗场所到提供健康导航系统的主动健康管理生 态平台。 围绕战略升级的底层逻辑、产品如何真正实现"线上+线下"融合以及商业闭环如何跑通等问题，《证券 日报》记者近日专访了盈康生命董事兼总经理马安捷。 打造"专属AI私人医生" 盈康生命成立于1998年，于2010年登陆深交所创业板，2019年公司实际控制人变更为海尔集团。在医疗 服务端，公司经营及管理着11家医疗机构。在器械端，公司围绕肿瘤"预/诊/治/康"关键场景布局放射治 疗、生命支持、影像增强、慢病治疗等产品线。 这种"从工具到供给侧变革"的判断，也体现在公司对AI底座的描述上。马安捷提到，盈康生命正在 以"盈康大脑"为智慧中枢，形成"算力与数据湖—能力组件—智能交互 ...

2025年，超声骨刀业务在销售业绩和净利润上均取得了快速的增长。公司国际化业务亦保持持续快速发 展。 三友医疗(688085.SH)披露2025年度业绩快报，公司实现营业总收入5.43亿元，同比增长19.66%;研发费 用8371.08万元，研发投入占比15.42%;实现归属于母公司所有者的净利润6328.95万元，同比增加 451.85%;实现归属于母公司所有者的扣除非经常性损益的净利润4966.71万元，与上年同期相比，实现 扭亏为盈。 ...

Integra LifeSciences (NasdaqGS:IART) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsChris Ward - Senior Director of Investor RelationsLea Knight - EVP and CFOMojdeh Poul - President and CEOConference Call ParticipantsRavi Misra - Research AnalystNone - AnalystNone - AnalystNone - AnalystOperatorGood day, and welcome to the Integra LifeSciences fourth quarter 2025 financial results. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be ...

Enovis (NYSE:ENOV) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsBen Berry - CFOCaitlin Cronin - Director of MedTech Equity ResearchDamien McDonald - CEOJoseph Conway - Equity Research AssociateKyle Rose - VP of Investor RelationsVijay Kumar - Senior Managing Director of Equity ResearchConference Call ParticipantsDanielle Antalffy - Senior AnalystJeff Johnson - Senior Research Analyst of Medical TechnologyKeith Hinton - Director and Senior Analyst of HealthcareRobbie Marcus - Senio ...

Enovis (NYSE:ENOV) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker6Good day, and welcome to the Enovis fourth quarter 2025 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press Star, then 1 on your touchtone phone. To withdraw your question, please press Star then 2 ...

Integra LifeSciences (NasdaqGS:IART) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker5Good day, and welcome to the Integra LifeSciences fourth quarter 2025 financial results. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question, please press star 1. To remove yourself from the queue, press star 1 1 again. This call may be recorded. I would now like to turn the call over to Chris Ward, Senior Director ...

新京报贝壳财经讯2月26日，安杰思发布业绩快报，2025年度公司实现营业总收入5.97亿元，同比下降 6.19%；归母净利润2.23亿元，同比下降24.06%。报告期内，公司所处的医疗器械行业因受到国内医保 集中带量采购和海外关税政策等行业因素的影响，公司主营业务所处的内镜微创诊疗领域受到行业竞争 加具的影响，致使公司2025年全年业绩阶段性承压。 ...

Core Viewpoint - Sanofi Bio is transforming into a "diabetes digital management expert" by leveraging its "Aikan Health" app as a user entry point, enhancing user engagement and retention, and building a valuable user base [1] Group 1: Business Strategy - The company aims to create a personalized and interactive health management ecosystem by integrating CGM data with AI technology and its existing multi-device layout, which includes blood glucose, uric acid, blood lipids, glycosylated hemoglobin, and blood pressure [1] - The commercialization of this ecosystem will depend on user base accumulation, cultivation of payment habits, deepening ecological cooperation, and improving service systems, indicating a long-term strategic layout [1] Group 2: Market Exploration - The company will explore and tap into different market demands and user habits during its development process, indicating a flexible approach to market needs [1] - Continuous exploration of the "biosensor + artificial intelligence + healthcare" new model will be pursued to promote a closed-loop management system for diabetes [1]

Teleflex (NYSE:TFX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsBradley Bowers - VP of Equity ResearchJayson Bedford - Managing Director of Equity ResearchJohn Deren - EVP and CFOLawrence Keusch - Vice President of Investor Relations and Strategy DevelopmentStuart Randle - Interim President and CEOTravis Steed - Managing Director of Medical Technology Equity ResearchConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMatthew O'Brien - Managi ...